Efzofitimod

N/A

Report date: 2024/01/11 16:51:54

Base Information

Drug NameEfzofitimod

Drug Alias NamestalarisefzofitimodiMod.Fc (aTyr Pharma)ATYR-1923KRP-R120

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionNeuropilin 2 modulators

TargetsNeuropilin 2

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Sarcoidosis, PulmonaryLung Diseases, Interstitial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto RicoNetherlands +[10]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesAtyr Pharma

China Registration ClassN/A

Develop Information

Active CompaniesAtyr Pharma Inc

Inactive CompaniesN/A

Active IndicationsSarcoidosis, PulmonaryLung Diseases, Interstitial

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A